XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.3
RESTRUCTURING
 6 Months Ended
Sep. 30, 2023
Restructuring and Related Activities [Abstract]  
RESTRUCTURING
5. RESTRUCTURING

On an ongoing basis, the Company reviews the global economy, the healthcare industry, and the markets in which it competes to identify opportunities for efficiencies, enhance commercial capabilities, align its resources and offer its customers better solutions. In order to realize these opportunities, the Company undertakes restructuring-type activities to transform its business.

In July 2019, the Board of Directors of the Company approved the Operational Excellence Program (the “2020 Program”) and delegated authority to the Company’s management to determine the detail of the initiatives that will comprise the program. During fiscal 2022, the Company revised the program to improve product and service quality, reduce cost principally in its manufacturing and supply chain operations and ensure sustainability while helping to offset impacts from a previously announced customer loss, rising inflationary pressures and effects of the COVID-19 pandemic. The Company expects to incur aggregate charges between $95 million and $105 million by the end of fiscal 2025 under the program. The majority of charges will result in cash outlays, including severance and other employee costs, and will be incurred as the specific actions required to execute these initiatives are identified and approved. During the three and six months ended September 30, 2023, the Company incurred $2.0 million and $4.2 million, respectively, of restructuring and restructuring related costs under this program. During the three and six months ended October 1, 2022, the Company incurred $3.1 million and $6.6 million, respectively, of restructuring and restructuring related costs under this program. Total cumulative charges under this program are $71.4 million.
The following table summarizes the activity for restructuring reserves related to the 2020 Program and prior programs for the six months ended September 30, 2023, substantially all of which relates to employee severance and other employee costs:
(In thousands)2020 ProgramPrior ProgramsTotal
Balance at April 1, 2023
$1,810 $340 $2,150 
Costs incurred, net of reversals57 18 75 
Payments(721)(27)(748)
Balance at September 30, 2023
$1,146 $331 $1,477 

The following presents the restructuring costs by line item within our accompanying unaudited Condensed Consolidated Statements of Income and Comprehensive Income:
 Three Months EndedSix Months Ended
(In thousands) September 30,
2023		October 1,
2022		September 30,
2023		October 1,
2022
Cost of goods sold$58 $29 $264 $(177)
Selling, general and administrative expenses28 136 (189)298 
Total$86 $165 $75 $121 

As of September 30, 2023, the Company had a restructuring liability of $1.5 million, of which approximately $1.1 million is payable within the next twelve months.

In addition to the restructuring expenses included in the table above, the Company also incurred costs that do not constitute restructuring costs under ASC 420, Exit and Disposal Cost Obligations, and which the Company instead refers to as restructuring related costs. These costs consist primarily of expenditures directly related to the restructuring actions.

The tables below present restructuring and restructuring related costs by reportable segment:
Restructuring costsThree Months EndedSix Months Ended
(In thousands) September 30, 2023October 1, 2022September 30, 2023October 1, 2022
Plasma$59 $— $(197)$(211)
Hospital— — 242 — 
Corporate27 165 30 332 
Total$86 $165 $75 $121 
Restructuring related costsThree Months EndedSix Months Ended
(In thousands) September 30, 2023October 1, 2022September 30, 2023October 1, 2022
Plasma$74 $108 $243 $748 
Blood Center28 16 73 18 
Hospital98 111 147 200 
Corporate1,747 2,794 3,688 5,585 
Total$1,947 $3,029 $4,151 $6,551 
Total restructuring and restructuring related costs$2,033 $3,194 $4,226 $6,672